FDA
-
-
-
-
-
-
-
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis
-
-
-
-
-
-
-
Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
-
-
-
-
-
-
-
Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

